London-based Sava Technologies has raised $19 million (~€16.6M) in a Series A round led by Balderton Capital and Pentland Ventures, with participation from Norrsken VC, JamJar, Italian Founders Fund, Athletico Ventures, and Exceptional Ventures.
The round brings Sava’s total funding to $32M, including public support from the UK and EU governments.
Democratizing CGMs with a pain-free, scalable alternative
Founded in 2019 by Imperial College bioengineers Renato Circi and Rafaël Michali, Sava is developing a modular, real-time biosensing platform designed to be worn on the skin — starting with a next-gen continuous glucose monitor (CGM) that eliminates the pain, invasiveness, and high cost of existing filament-based systems.
Advertisement
Early clinical trials show accurate 10-day wear
Sava’s sensor tracks glucose and other key biomarkers through the skin, delivering molecular insights in real time via mobile. Early clinical trials with 25 patients have shown accurate readings for up to 10 days of continuous use. The company is gearing up for larger regulatory studies and CE/FDA submission.
Platform play: glucose today, multi-molecule tomorrow
While the initial product focuses on diabetes management,the company’s underlying technology supports multi-molecule detection — enabling future expansion into broader preventative and personalized health monitoring. “Glucose is only the beginning,” said co-founder Circi. “This is the foundation for real-time health tracking at the molecular level.”
Team includes CGM veterans from Abbott and Dexcom
Sava has grown to over 60 employees, including former engineers and clinical experts from Abbott and Dexcom. The new capital will fund automated manufacturing scale-up, regulatory preparation, and commercial launch planning for the company’s wearable platform.
Addressing a $11B+ market with <1% adoption
Though CGMs generate over $11 billion annually, only 1% of diabetic patients currently use them due to high cost and discomfort. Sava aims to dramatically expand adoption with a low-cost, non-invasive, and highly scalable alternative, backed by public and private capital.
